Details for Patent: 12,138,351
✉ Email this page to a colleague
Which drugs does patent 12,138,351 protect, and when does it expire?
Patent 12,138,351 protects LAZCLUZE and is included in one NDA.
This patent has eighteen patent family members in fourteen countries.
Summary for Patent: 12,138,351
| Title: | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
| Abstract: | Provided herein are pharmaceutical compositions for oral administration comprising N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide or a pharmaceutically acceptable salt, hydrate, or solvate thereof as an active ingredient; and a combination of (i) a cellulose derivative and (ii) a sugar or polyol as diluents. The disclosed compositions are characterized by improved manufacturability, while maintaining the pharmaceutical benefits of minimizing the effect according to changes in pH environment in the stomach, possessing excellent stability, and exhibiting good bioavailability. |
| Inventor(s): | Jacqueline Maximilien, Gopal Rajan |
| Assignee: | Janssen Biotech Inc |
| Application Number: | US17/228,753 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 12,138,351
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | LAZCLUZE | lazertinib mesylate | TABLET;ORAL | 219008-001 | Aug 19, 2024 | RX | Yes | No | 12,138,351 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Janssen Biotech | LAZCLUZE | lazertinib mesylate | TABLET;ORAL | 219008-002 | Aug 19, 2024 | RX | Yes | Yes | 12,138,351 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,138,351
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 121828 | ⤷ Start Trial | |||
| Australia | 2021257662 | ⤷ Start Trial | |||
| Australia | 2025203347 | ⤷ Start Trial | |||
| Brazil | 112022020609 | ⤷ Start Trial | |||
| Canada | 3180184 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
